Pharmacotherapy and treatment options for HIV-associated nephropathy

Steven Menez, Mohamad Hanouneh, Blaithin A. McMahon, Derek M Fine, Mohamed Atta

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Human immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patients without HIVAN. Areas covered: The epidemiology of HIVAN, particularly risk assessment, will be explored in this review. Further, the pathogenesis of HIVAN, from viral-specific renal expression to the role of genetics as well as characteristic renal pathology will be described. Diagnosis and management of HIVAN will be addressed, with an emphasis on various treatment strategies including medication, dialysis, and kidney transplantation. Expert opinion: HIVAN is associated with a high risk for progression to ESRD and increased mortality. The backbone of HIVAN therapy remains combined anti-retroviral therapy (cART), while adjunctive therapies including RAAS blockade and prednisone, should be considered. In those who progress to ESRD, dialysis remains the mainstay of management, though increasing evidence has demonstrated that kidney transplantation can be effective in those with controlled HIV disease.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

AIDS-Associated Nephropathy
Drug Therapy
Chronic Kidney Failure
Therapeutics
HIV
Kidney Transplantation
Mortality
Kidney
Expert Testimony
Kidney Diseases
Virus Diseases
CD4 Lymphocyte Count
Prednisone
Viral Load
Renal Dialysis
Dialysis
Epidemiology

Keywords

  • dialysis
  • ESRD
  • HIV
  • HIVAN
  • kidney biopsy
  • transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy and treatment options for HIV-associated nephropathy. / Menez, Steven; Hanouneh, Mohamad; McMahon, Blaithin A.; Fine, Derek M; Atta, Mohamed.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 1, 01.01.2018, p. 39-48.

Research output: Contribution to journalReview article

@article{2c8d89c46e2a4b48948c7d5d22513eee,
title = "Pharmacotherapy and treatment options for HIV-associated nephropathy",
abstract = "INTRODUCTION: Human immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patients without HIVAN. Areas covered: The epidemiology of HIVAN, particularly risk assessment, will be explored in this review. Further, the pathogenesis of HIVAN, from viral-specific renal expression to the role of genetics as well as characteristic renal pathology will be described. Diagnosis and management of HIVAN will be addressed, with an emphasis on various treatment strategies including medication, dialysis, and kidney transplantation. Expert opinion: HIVAN is associated with a high risk for progression to ESRD and increased mortality. The backbone of HIVAN therapy remains combined anti-retroviral therapy (cART), while adjunctive therapies including RAAS blockade and prednisone, should be considered. In those who progress to ESRD, dialysis remains the mainstay of management, though increasing evidence has demonstrated that kidney transplantation can be effective in those with controlled HIV disease.",
keywords = "dialysis, ESRD, HIV, HIVAN, kidney biopsy, transplantation",
author = "Steven Menez and Mohamad Hanouneh and McMahon, {Blaithin A.} and Fine, {Derek M} and Mohamed Atta",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/14656566.2017.1416099",
language = "English (US)",
volume = "19",
pages = "39--48",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Pharmacotherapy and treatment options for HIV-associated nephropathy

AU - Menez, Steven

AU - Hanouneh, Mohamad

AU - McMahon, Blaithin A.

AU - Fine, Derek M

AU - Atta, Mohamed

PY - 2018/1/1

Y1 - 2018/1/1

N2 - INTRODUCTION: Human immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patients without HIVAN. Areas covered: The epidemiology of HIVAN, particularly risk assessment, will be explored in this review. Further, the pathogenesis of HIVAN, from viral-specific renal expression to the role of genetics as well as characteristic renal pathology will be described. Diagnosis and management of HIVAN will be addressed, with an emphasis on various treatment strategies including medication, dialysis, and kidney transplantation. Expert opinion: HIVAN is associated with a high risk for progression to ESRD and increased mortality. The backbone of HIVAN therapy remains combined anti-retroviral therapy (cART), while adjunctive therapies including RAAS blockade and prednisone, should be considered. In those who progress to ESRD, dialysis remains the mainstay of management, though increasing evidence has demonstrated that kidney transplantation can be effective in those with controlled HIV disease.

AB - INTRODUCTION: Human immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patients without HIVAN. Areas covered: The epidemiology of HIVAN, particularly risk assessment, will be explored in this review. Further, the pathogenesis of HIVAN, from viral-specific renal expression to the role of genetics as well as characteristic renal pathology will be described. Diagnosis and management of HIVAN will be addressed, with an emphasis on various treatment strategies including medication, dialysis, and kidney transplantation. Expert opinion: HIVAN is associated with a high risk for progression to ESRD and increased mortality. The backbone of HIVAN therapy remains combined anti-retroviral therapy (cART), while adjunctive therapies including RAAS blockade and prednisone, should be considered. In those who progress to ESRD, dialysis remains the mainstay of management, though increasing evidence has demonstrated that kidney transplantation can be effective in those with controlled HIV disease.

KW - dialysis

KW - ESRD

KW - HIV

KW - HIVAN

KW - kidney biopsy

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85043369107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043369107&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1416099

DO - 10.1080/14656566.2017.1416099

M3 - Review article

C2 - 29224373

AN - SCOPUS:85043369107

VL - 19

SP - 39

EP - 48

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -